Trials / Completed
CompletedNCT02623777
Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome
Evaluation of the Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome and the Contribution of Short-chain Fatty Acids Production
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- KU Leuven · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
During this project the investigators will evaluate whether the effects of arabinoxylan oligosaccharides (AXOS) consumption on insulin resistance in participants with metabolic syndrome can be explained by the production of short-chain fatty acids (SCFA). Secondly, the investigators will evaluate whether changes in gut hormone production might explain the effect on insulin resistance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Arabinoxylan oligosaccharides | Arabinoxylan oligosaccharides administered |
| DIETARY_SUPPLEMENT | Short chain fatty acids | Short chain fatty acids administered |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-10-01
- Completion
- 2015-11-01
- First posted
- 2015-12-08
- Last updated
- 2015-12-08
Source: ClinicalTrials.gov record NCT02623777. Inclusion in this directory is not an endorsement.